Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Dermatology · Mycosis Fungoides

Understanding Your Diagnosis: Mycosis Fungoides and Its Variants

At a Glance

Mycosis fungoides is a usually slow-growing skin lymphoma, not a fungal infection. Early disease often stays in the skin, but its outlook and treatment depend on the stage, variant, blood involvement, and response to skin-directed therapy.

Receiving a diagnosis of “lymphoma” is a heavy moment that often triggers an immediate sense of panic. However, it is important to understand that Mycosis Fungoides (MF) is a primary cutaneous T-cell lymphoma, meaning it begins in the skin and, for many early-stage patients, remains there for many years [1][2].

MF is a rare condition, with an estimated incidence of only about 4 cases per million people each year [3]. Because it is so uncommon and often looks like more ordinary skin issues, most patients have already been on a long journey before reaching this diagnosis.

Why Skin Lymphoma Is Different

In most lymphomas, the cancerous cells circulate heavily through the lymph nodes and internal organs. In contrast, classic MF involves T-cells (a type of white blood cell) that localize to the skin [1]. This makes early classic MF an indolent (slow-growing) disease. However, risk varies with stage, variant, blood involvement, and large-cell transformation, and it remains a real lymphoma that can progress.

For many people with early-stage MF, the disease-specific survival rate is excellent. One long-term historical cohort study found that the 5-year survival rate for early-stage disease in their group was over 97%, and even after 20 years, it remained as high as 82.6% [4]. (Keep in mind that survival estimates vary by stage and study, and your specialist must interpret what they mean for your situation). This is why doctors often treat early-stage MF with skin-directed therapies—such as light therapy or medicated creams—rather than the aggressive systemic treatments used for internal cancers [5][6].

The Path to Diagnosis

The journey to an MF diagnosis is rarely a straight line. Because early MF symptoms—red, itchy patches or slightly raised plaques—closely resemble common conditions like eczema, psoriasis, or contact dermatitis, it is frequently misdiagnosed at first [7][8].

It is common for there to be a significant delay between the first symptom and a final answer; one study noted a median diagnostic delay of 2.3 years [9]. In many cases, the first biopsy is inconclusive because the early signs of MF are so subtle that they blend among normal inflammatory cells. It often takes multiple biopsies and a specialist known as a dermatopathologist (a doctor who specializes in looking at skin samples under a microscope) to confirm the diagnosis through clinicopathologic correlation—matching what the doctor sees on your skin with what is seen under the microscope [10][11].

Common Misunderstandings

When you search for “lymphoma,” you may find information that doesn’t apply to your situation. Here are a few key facts to help clear up common misconceptions:

  • It is not a fungus: The name “Mycosis Fungoides” is a historical relic from the 1800s because the skin lesions sometimes looked like mushrooms to early doctors. It is not an infection and you cannot “catch” it from or give it to anyone else [12].
  • It rarely jumps to organs quickly: While roughly 20–30% of cases in certain cohorts progressed to more advanced stages over time, the majority of early-stage patients do not experience rapid spread to their internal organs [13][4].
  • “Watchful Waiting” is a valid strategy: Because the disease is so slow-moving, your care team may focus on managing your symptoms and monitoring your skin rather than using aggressive treatment options that could have more side effects than the disease itself.

Understanding Variants

You may hear your doctor use different names for your specific type of MF. These variants simply describe how the T-cells are behaving in your skin:

  • Folliculotropic MF: The T-cells gather around hair follicles, sometimes causing hair loss or acne-like bumps. While this can sometimes be more resistant to certain light therapies, many patients still respond well to targeted treatment [14][15].
  • Pagetoid Reticulosis: A very localized version of MF that often appears as a single slow-growing patch, usually on the hands or feet, and generally has a very positive outlook [16].
  • Granulomatous Slack Skin: An extremely rare variant that causes the skin to become loose or “lax” in certain areas [17].

Regardless of the variant, the most important factor in your care is your stage (how much of your skin is involved) and how your body responds to the initial treatments [18][5]. Diagnosis is the first step toward managing a chronic condition, rather than an immediate medical emergency.

Common questions in this guide

Is mycosis fungoides a fungal infection or something I can spread?
No. Mycosis fungoides is a rare type of lymphoma that begins in the skin and involves abnormal T cells; despite its name, it is not caused by a fungus. It is not an infection and cannot be caught from or passed to another person.
What are the different mycosis fungoides variants?
Variants describe where or how abnormal T cells appear in the skin. Folliculotropic MF involves hair follicles and may cause hair loss or acne-like bumps; Pagetoid reticulosis is often a single slow-growing patch on a hand or foot; and granulomatous slack skin causes loose skin in certain areas. The variant, along with stage and response to treatment, helps guide care.
Why can it take multiple biopsies to diagnose mycosis fungoides?
Early MF can look like eczema, psoriasis, or contact dermatitis, and abnormal cells may be subtle in a small skin sample. A first biopsy may be inconclusive, so doctors sometimes repeat biopsies and ask a dermatopathologist to compare the skin findings with the microscope results. This combined review is called clinicopathologic correlation.
Can early mycosis fungoides spread beyond the skin?
Early MF often remains in the skin for many years, and most people with early-stage disease do not experience rapid spread to internal organs. However, MF can progress, and the outlook depends on stage, the variant, blood involvement, and whether large-cell transformation develops. Regular follow-up helps the care team monitor for change.
How is early mycosis fungoides usually treated?
Early-stage MF is often treated with therapies directed at the skin, such as light therapy or medicated creams, including topical steroids. Because the disease may be slow-growing, careful monitoring may also be appropriate when treatment side effects could outweigh the benefit. The best approach depends on stage, variant, symptoms, and response.
What does my mycosis fungoides stage tell me?
Stage describes how much of the skin is involved and whether disease has been found in the blood or beyond the skin. It is one of the most important factors used to estimate outlook and choose treatment, together with the MF variant and response to initial therapy. Your specialist can explain how your stage applies to your individual situation.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on mycosis fungoides variant.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific stage and variant (e.g., classic MF, folliculotropic, etc.), and how does that affect my treatment plan?
  2. 2.Has my biopsy been reviewed by a dermatopathologist who specializes in cutaneous lymphomas?
  3. 3.Based on my current stage, what is the likelihood of this progressing beyond my skin, and what symptoms should I watch for?
  4. 4.Why are you recommending skin-directed therapy (like light therapy or topical steroids) instead of systemic treatments like chemotherapy?
  5. 5.How long do you expect it will take before we see a visible response to the treatment?

References

References (18)
  1. 1

    High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides.

    de Masson A, O'Malley JT, Elco CP, et al.

    Science translational medicine 2018; (10(440)) doi:10.1126/scitranslmed.aar5894.

    PMID: 29743350
  2. 2

    Diagnosis of Early Mycosis Fungoides.

    Miyagaki T

    Diagnostics (Basel, Switzerland) 2021; (11(9)) doi:10.3390/diagnostics11091721.

    PMID: 34574062
  3. 3

    Mycosis fungoides of the vulva.

    Tjalma WAA, Janssens M, Dam K, et al.

    Northern clinics of Istanbul 2021; (8(1)):101-105 doi:10.14744/nci.2020.12129.

    PMID: 33623880
  4. 4

    Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort.

    Miyashiro D, Sanches JA

    International journal of dermatology 2022; (61(4)):442-454 doi:10.1111/ijd.15865.

    PMID: 34435672
  5. 5

    How I treat mycosis fungoides and Sézary syndrome.

    Whittaker S, Hoppe R, Prince HM

    Blood 2016; (127(25)):3142-53 doi:10.1182/blood-2015-12-611830.

    PMID: 27151889
  6. 6

    NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

    Mehta-Shah N, Horwitz SM, Ansell S, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(5)):522-536.

    PMID: 32380458
  7. 7

    Reflectance confocal microscopy as a first-line diagnostic technique for mycosis fungoides.

    Yeager DG, Noor O, Rao BK

    Cutis 2018; (102(1)):56-58.

    PMID: 30138497
  8. 8

    Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion.

    Hodak E, Geskin L, Guenova E, et al.

    American journal of clinical dermatology 2023; (24(1)):5-14 doi:10.1007/s40257-022-00732-w.

    PMID: 36399227
  9. 9

    Delay in the histopathologic diagnosis of mycosis fungoides.

    Skov AG, Gniadecki R

    Acta dermato-venereologica 2015; (95(4)):472-5 doi:10.2340/00015555-1971.

    PMID: 25228392
  10. 10

    CD8-positive Mycosis Fungoides Masquerading as Pyoderma Gangrenosum.

    Saha M, Jain BB, Chattopadhyay S, Podder I

    Indian journal of dermatology 2016; (61(5)):580 doi:10.4103/0019-5154.190126.

    PMID: 27688458
  11. 11

    When mycosis fungoides seems not to be within the spectrum of clinical and histopathological differential diagnoses.

    Di Prete M, Michelerio A, Lora V, et al.

    Dermatology reports 2024; (16(Suppl 2)):10008 doi:10.4081/dr.2024.10008.

    PMID: 39295886
  12. 12

    A historical review of mycosis fungoides: from Alibert to mogamulizumab.

    Johnson NA, Fariyike O, Mistry K, et al.

    Skin health and disease 2026; (6(1)):30-34 doi:10.1093/skinhd/vzaf099.

    PMID: 41646541
  13. 13

    Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma.

    Rindler K, Jonak C, Alkon N, et al.

    Molecular cancer 2021; (20(1)):124 doi:10.1186/s12943-021-01419-2.

    PMID: 34583709
  14. 14

    Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group.

    van Santen S, van Doorn R, Neelis KJ, et al.

    The British journal of dermatology 2017; (177(1)):223-228 doi:10.1111/bjd.15355.

    PMID: 28132406
  15. 15

    Cicatricial Alopecia Related to Folliculotropic Mycosis Fungoides.

    Kreutzer KM, Effendy I

    Dermatology and therapy 2020; (10(5)):1175-1180 doi:10.1007/s13555-020-00429-0.

    PMID: 32833161
  16. 16

    Unusual variants of mycosis fungoides.

    Virmani P, Myskowski PL, Pulitzer M

    Diagnostic histopathology (Oxford, England) 2016; (22(4)):142-151 doi:10.1016/j.mpdhp.2016.04.004.

    PMID: 29225700
  17. 17

    Mycosis Fungoides and Granulomatous Slack Skin: A Single Entity With Distinct Clinical Phenotypes.

    Bakr F, Ziaj S, Cardoso J, et al.

    The American Journal of dermatopathology 2024; (46(1)):14-20 doi:10.1097/DAD.0000000000002590.

    PMID: 37987779
  18. 18

    Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management.

    Miyashiro D, Sanches JA

    Frontiers in oncology 2023; (13()):1141108 doi:10.3389/fonc.2023.1141108.

    PMID: 37124514

This page is for informational purposes only and does not constitute medical advice. Your dermatologist, dermatopathologist, or oncology team should interpret your biopsy, stage, variant, and treatment options.